Maury Raycroft

“And maybe just one follow-up for the price. Do you expect that some payers are going to require an outcomes-based reimbursement arrangement? And what could that look like?”

“Maybe I'll just ask one on the term loan negotiations. Laura, you mentioned potential for a waiver. What do those discussions look like, and what could updated obligations look like if there's a waiver, and what is the likelihood of that?”

“So, I'm wondering if you can provide more color on what is gating the update. Is it operational related to the clinical study or data analysis, or are you awaiting additional regulatory clarity on the potential development path?”

“So I'm wondering if you can provide more color on what is gating the update. Is it operational related to the clinical study or data analysis, or are you awaiting additional regulatory clarity on the potential development path?”

“And if so, are you seeing any objective changes in EEG activity that correspond with the higher level improvements in seizures that were reported at IRSF? And how will seizure activity be assessed more rigorously in the pivotal versus Part A?”